Key EU Committee Backs AstraZeneca Diabetes Drug
27 May 2016 - 10:42PM
Dow Jones News
LONDON--AstraZeneca PLC (AZN.LN) Friday said a key committee of
the European Medicines Agency had issued an opinion recommending
approval of "saxa/dapa" tablets for treating adults with Type-2
diabetes.
The bio-pharmaceutical company said the positive opinion from
the Committee for Medicinal Products for Human Use would now be
reviewed by the European Commission, which holds the power to
approve medicines for the European Union.
Saxa/dapa is a fixed-dose combination of saxagliptin and
dapagliflozin, the company said.
Shares at 1145 GMT were down 43.50 pence, or 1.1%, at 3968
pence, valuing the company at 50.17 billion pounds ($73.72
billion).
Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter
@OlgaCotaga
(END) Dow Jones Newswires
May 27, 2016 08:27 ET (12:27 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024